{
  "source": "PA-Notification-Ruconest.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1142-11\nProgram Prior Authorization/Notification\nMedications Ruconest® (C1 esterase inhibitor [recombinant])\nP&T Approval Date 8/2014, 8/2015, 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 7/2021,\n7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nRuconest (C1 esterase inhibitor [recombinant]) is indicated for the treatment of acute attacks in\nadult and adolescent patients with hereditary angioedema (HAE). Effectiveness was not\nestablished in HAE patients with laryngeal attacks.1\n2. Coverage Criteriaa:\nA. Ruconest will be approved based on all of the following criteria:\n1. Diagnosis of hereditary angioedema (HAE)\n-AND-\n2. For the treatment of acute HAE attacks\n-AND-\n3. Not used in combination with other products indicated for acute HAE attacks (e.g.,\nBerinert, Firazyr, or Kalbitor)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limitations may be in place.\n4. References:\n1. Ruconest [package insert]. Bridgewater, NJ: Pharming Healthcare, Inc.; April 2020\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Ruconest (C1 esterase inhibitor\n[recombinant])\nChange Control\n8/2014 New program.\n8/2015 Annual review. Updated references.\n7/2016 Annual review with no changes to the coverage criteria. Updated\nbackground and references.\n7/2017 Annual review. No changes.\n7/2018 Annual review. No changes to the coverage criteria. Updated\nreferences",
    "nual review with no changes to the coverage criteria. Updated\nbackground and references.\n7/2017 Annual review. No changes.\n7/2018 Annual review. No changes to the coverage criteria. Updated\nreferences.\n7/2019 Annual review. No changes to the program.\n7/2020 Annual review. No changes to coverage criteria.\n7/2021 Annual review. No changes to coverage criteria.\n7/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote. Updated reference.\n7/2023 Annual review. Revised wording of criteria without change to clinical\nintent.\n7/2024 Annual review. No changes to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}